Approval of monoclonal antibodies for the treatment of Alzheimer's and hematological diagnostic tests to identify it signify the onset of a new era in the diagnosis and treatment of the disease, as noted in an article in The Lancet magazine.
However, experts call for a rapid reform of healthcare systems, political and social attitudes to fully utilize the above potential.
The article states that new treatments with monoclonal antibodies can slow Alzheimer's progression at a level comparable to the effectiveness of cancer, rheumatoid arthritis and multiple sclerosis.
However, the high cost of drugs, complex examination requirements, non -optimal care for behavioral problems and lack of resources raise the risk of patients with Alzheimer's back.
In addition, there are improvements in the prevention of the disease by identifying people at high risk of its occurrence, but it is emphasized that most cases occur in people with low or normal risk, which makes it necessary to reduce the risk to the entire population, such as alcohol and alcohol restrictions.
Scientists are calling for coordinated global action so that the rapid pace of (scientific) progress is accompanied by reforms at the level of health care providers, politics and society.
